CONCORDBIO · Healthcare
Concord Biotech Ltd. reported revenue of ₹310 cr for July to September 2024, +18.3% on the year and +43.5% on the quarter.
Operating profit (EBITDA) was ₹137 cr, a margin of 44.2%, −123 bps on the year and +669 bps on the quarter. Over the last 6 quarters the margin has ranged from 36.9% to 45.4%, averaging 41.7%. Operating costs grew +21.0%, faster than revenue at +18.3%, so operating profit grew less than sales.
Net profit was ₹99.0 cr, +17.9% on the year and +70.7% on the quarter, with earnings per share of ₹9.43. Profit before other income, one-offs and tax grew 17.1%, so the profit growth came from the business itself. The tax rate of 26% is in line with its recent average.
On earnings per share of ₹31.42 over the last four quarters, the stock at ₹596.80 trades at 19.0 times trailing earnings.
Written from the quarterly statements. The filing read adds the balance sheet and cash flow filed with this quarter, the auditor's review, segment results, one-off items line by line and what management said on the call.
No check fired. That is a statement about the checks below, not a verdict on the company.
Could not run on this quarter: Exceptional items that recur, Cash behind the profit, Receivables against sales, Inventory against sales, Borrowing while holding cash, Auditor's review or audit report, IPO money used as stated, Related-party transactions, Exits, postponements, restatements, Promoter pledges and allotments, Earlier promises against delivery, When the results were filed. Most need the filing read (balance sheet, cash flow, auditor, disclosures).
Net profit a year ago, each driver's change, and net profit now. Blue added profit, red took it away.
This quarter's filing carries a balance sheet and a cash flow statement. The cash, receivables and borrowing checks run once the filing read is in.
| Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 | Q2 FY27 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | ₹241 cr | ₹319 cr | ₹216 cr | ₹310 cr | ₹244 cr | ₹430 cr | ₹204 cr | ₹247 cr | ₹278 cr | ₹326 cr | ₹261 cr | ₹312 cr |
| YoY | — | — | +11% | +18% | +1% | +35% | −6% | −20% | +14% | −24% | +28% | +26% |
| EBITDA margin | 44.0% | 42.0% | 37.5% | 44.2% | 40.2% | 44.2% | 29.9% | 36.8% | 36.7% | 37.4% | 33.3% | 35.3% |
| Other income, % of PBT | 8% | 8% | 13% | 8% | 15% | 5% | 25% | 15% | 8% | 14% | 16% | 10% |
| Exceptional items | — | — | — | — | — | — | — | — | — | — | — | — |
| Tax rate | 26% | 26% | 25% | 26% | 25% | 23% | 26% | 26% | 25% | 24% | 26% | 26% |
| Net profit | ₹75.0 cr | ₹97.0 cr | ₹58.0 cr | ₹99.0 cr | ₹74.0 cr | ₹142 cr | ₹43.0 cr | ₹63.0 cr | ₹68.0 cr | ₹90.0 cr | ₹61.0 cr | ₹76.0 cr |
| YoY | — | — | +21% | +18% | −1% | +46% | −26% | −36% | −8% | −37% | +42% | +21% |
| Core profit YoY | — | — | +17% | +17% | −9% | +47% | −37% | −41% | −1% | −42% | +60% | +26% |
| EPS | ₹7.13 | ₹9.29 | ₹5.57 | ₹9.43 | ₹7.08 | ₹13.57 | ₹4.07 | ₹6.01 | ₹6.48 | ₹8.60 | ₹5.85 | ₹3.62 |
| Flags | · | · | ✓ | ✓ | 1 | ✓ | 1 | 1 | 1 | 1 | ✓ | ✓ |
Each quarter is read with the same rules. Balance-sheet and cash checks run on half-year and annual quarters; filing-read checks run where a read exists.
Concord Biotech Ltd. reported revenue of ₹310 cr (+18.3% on the year) and net profit of ₹99.0 cr (+17.9% on the year) for July to September 2024.
Profit before other income, exceptional items and tax moved +17.1% on the year, against +17.9% for reported profit.
None of the 7 checks that could run raised a question.
No. FinMinutes reports what was filed and the questions the numbers raise. It does not recommend buying, selling or holding any security.
Numbers as filed with the exchanges, read by rules. Every flag is a question with its source, not an accusation. FinMinutes is a financial data and analytics platform; nothing here is a recommendation to buy, sell or hold any security. How each check works.